Abstract:Background: Advances in ultrasensitive detection of phosphorylated tau (p-tau) in plasma has enabled the use of blood tests to measure Alzheimer's disease (AD) biomarker changes. Examination of postmortem brains of participants with antemortem plasma p-tau levels remains critical to understanding comorbid and AD-specific contribution to these biomarker changes. Methods: We analyzed 35 population-based Mayo Clinic Study of Aging participants with plasma p-tau at threonine 181 and threonine 217 (p-tau181, p-tau217) available within 3 years of death. Autopsied participants included cognitively unimpaired, mild cognitive impairment, AD dementia, and non-AD neurodegenerative disorders. Global neuropathologic scales of tau, amyloid-β, TDP-43, and cerebrovascular disease were examined. Regional digital pathology measures of tau (phosphorylated threonine 181 and 217 [pT181, pT217]) and amyloid-β (6F/3D) were quantified in hippocampus and parietal cortex. Neurotransmitter hubs reported to influence development of tangles (nucleus basalis of Meynert) and amyloid-β plaques (locus coeruleus) were evaluated. Results: The strongest regional associations were with parietal cortex for tau burden (p-tau181 R = 0.55, p = 0.003; p-tau217 R = 0.66, p < 0.001) and amyloid-β burden (p-tau181 R = 0.59, p < 0.001; p-tau217 R = 0.71, p < 0.001). Linear regression analysis of global neuropathologic scales explained 31% of variability in plasma p-tau181 (Adj. R2 = 0.31) and 59% in plasma p-tau217 (Adj. R2 = 0.59). Neither TDP-43 nor cerebrovascular disease global scales independently contributed to variability. Global scales of tau pathology (β-coefficient = 0.060, p = 0.016) and amyloid-β pathology (β-coefficient = 0.080, p < 0.001) independently predicted plasma p-tau217 when modeled together with co-pathologies, but only amyloid-β (β-coefficient = 0.33, p = 0.021) significantly predicted plasma p-tau181. While nucleus basalis of Meynert neuron count/mm2 was not associated with plasma p-tau levels, a lower locus coeruleus neuron count/mm2 was associated with higher plasma p-tau181 (R = -0.50, p = 0.007) and higher plasma p-tau217 (R = -0.55, p = 0.002). Cognitive scores (Adj. R2 = 0.25-0.32) were predicted by the global tau scale, but not by the global amyloid-β scale or plasma p-tau when modeled simultaneously. Conclusions: Higher soluble plasma p-tau levels may be the result of an intersection between insoluble deposits of amyloid-β and tau accumulation in brain, and may be associated with locus coeruleus degeneration.

Genome-wide Association Study Identifies MAPT Locus Influencing Human Plasma Tau Levels.

Genome-wide Association Study Identifies APOE Locus Influencing Plasma P-Tau181 Levels

Meta-analysis of the association between variants in MAPT and neurodegenerative diseases.

MAPT Rs242557 Variant is Associated with Hippocampus Tau Uptake on 18F-AV-1451 PET in Non-Demented Elders.

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease

Association Analysis of GSK3B and MAPT Polymorphisms with Alzheimer's Disease in Han Chinese

Genome-wide Association Study of Brain Tau Deposition As Measured by 18F-Flortaucipir Positron Emission Tomography Imaging.

Association analysis of MAPK1 gene and Alzheimer's disease in Han Chinese

Genome-wide Association Study of Hippocampal Atrophy Rate in Non-Demented Elders

Further validation of the association between MAPT haplotype-tagging polymorphisms and Alzheimer's disease: neuropsychological tests, cerebrospinal fluid biomarkers, and APOE genotype

Genome-wide scan of Flortaucipir PET levels finds associated with cerebral tau deposition

Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

Association Of The Tauopathy Gwas Loci With Alzheimer'S Disease In China

A genome-wide association study of longitudinal change in CSF tau among non-demented elderly

Association Between MAPT Haplotype and Memory Function in Patients with Parkinson's Disease and Healthy Aging Individuals.

Genome-wide scan of Flortaucipir PET levels finds JARID2 associated with cerebral tau deposition

Association study of candidate gene polymorphisms of tau protein pathway with amnestic mild cognitive impairment

CYP1B1 - RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET

MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy

An Exploratory Study on STX 6 , MOBP , MAPT , and EIF 2 AK 3 and Late-Onset Alzheimer ’ S Disease

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy